secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009826
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M
--------------------------------------------------------------------------------

- Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.
- Preliminary Q4 IBTROZI net revenue $15.7M; total $24.7M since June 2025 launch; 432 new patient starts.
- Preliminary cash $529.2M at Dec 31, 2025; received $25M milestone from Nippon Kayaku.
- MAA for taletrectinib in Europe expected H1 2026; first €25M milestone upon EU approval.
- Company continues enrollment of safusidenib phase 3 study in IDH1-mutant gliomas; full FY2025 results due March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/0001193125-26-009826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer